Education
About Us
Working with TipRanks
Follow Us
Elekta AB (EKTAY)
OTHER OTC:EKTAY
EKTAY Stock Chart & Stats
$6.37
-$0.10(-1.78%)
At close: 4:00 PM EST
$6.37
-$0.10(-1.78%)
Day’s Range― - ―
52-Week Range$4.42 - $6.88
Previous CloseN/A
Volume122.00
Average Volume (3M)73.00
Market Cap
$2.55B
Enterprise Value$27.50B
Total Cash (Recent Filing)$2.56B
Total Debt (Recent Filing)$7.34B
Price to Earnings (P/E)567.4
Beta1.26
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding368,588,000
10 Day Avg. Volume0
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)2.12
Price to Sales (P/S)1.04
P/FCF Ratio17.69
Enterprise Value/Market Cap10.79
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit4.33
Enterprise Value/Ebitda14.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product Approvals & LaunchesU.S. FDA approval for Elekta Evo is a structural commercial catalyst: it expands the company’s addressable market in the largest radiotherapy market, supports durable capital-equipment sales, drives follow-on service and upgrade revenue, and strengthens competitive positioning for multi-year hospital purchasing cycles.
Margin Improvement & Cost ProgramSustained gross and cash EBIT margin improvement plus a structural SEK >500m run-rate savings program indicate operating leverage. If the operating-model changes and cost savings fully materialize, they can permanently raise margin floors, improving resilience to cyclical equipment demand over the next 2–6 months.
Solid Cash GenerationConsistent operating and free cash flow, and a YTD net-debt reduction, provide durable financial flexibility. Strong cash conversion supports reinvestment in R&D, service infrastructure and funding of restructuring costs, cushioning profitability swings tied to lumpy capital-equipment sales cycles.
Bears Say
FX And Tariff HeadwindsMaterial currency translation and tariff impacts are structural risks given Elekta’s global footprint. Persistent FX volatility and tariff exposure can subtract from reported growth and compress margins even if underlying demand recovers, complicating multi-period planning and reducing the cash-to-earnings translation.
Weakened Profitability / TTM Net LossA move to a TTM net loss after prior profitable years signals diminished earnings quality. Persistent margin compression reduces retained earnings and ROE, limits capital allocation optionality, and increases sensitivity to cyclical equipment demand and one-off charges over the medium term.
Restructuring Charges & Rising LeverageWhile aimed at structural savings, the sizable restructuring charge and remaining cash outlays will weigh on near-term reported earnings and cash. Combined with a modestly higher leverage profile, this reduces financial flexibility if execution or market recovery is slower than planned.
Elekta AB News
EKTAY FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was $4.42 and its highest was $6.88 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is $2.55B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Jun 03, 2026 which is in 86 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Mar 05, 2026. The company reported $0.003 earnings per share for the quarter, beating the consensus estimate of N/A by $0.003.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB pays a Semiannually dividend of $0.064 which represents an annual dividend yield of 0.21%. See more information on Elekta AB dividends here
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,588,000 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of $0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.228%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in EKTAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elekta AB Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.41%
12-Months-Change
Fundamentals
Return on Equity
2.57%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
EKTAY Company Deck
EKTAY Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: clear commercial and operational positives (product approvals and launches, China recovery, improved gross margin and strong cash EBIT momentum, healthy book-to-bill and YTD cash flow improvement) alongside meaningful near-term headwinds (large FX and tariff impacts, a SEK 417m restructuring charge with further P&L effects, Americas revenue decline and some regional slowdowns). Management reiterated guidance, outlined structural cost savings (>SEK 500m run-rate) and emphasized execution of a new operating model. Given the mix of encouraging execution/operational improvements and significant external and one-time pressures, the tone is constructive but cautious.View all EKTAY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---